Jeronimo Rafael Rodríguez-Cid1*, Marisol Arroyo-Hernandez2, Rodrigo Rafael Flores- Mariñelarena3, Carlos Jesus Castro-Lopez4, Jorge Arturo Alatorre-Alexander1, Luis Martínez- Barrera1, Sergio Monraz-Perez5, Carla Paola Sanchez-Ríos1, Maria del Rosario Flores-Soto1, Erika Sagrario Peña-Mirabal6, Lya Edith Pensado-Piedra7, Aloisia Paloma Hernandez- Morales7, Sonia Carrasco-Cara Chards8 and Patricio Javier Santillan-Doherty5
1Department of Oncology, National Institute of Respiratory Diseases (INER), Mexico 2Functional Unit of Thoracic Oncology, National Institute of Cancerology, Mexico 3Department of Internal Medicine, Southern Medical Clinic Foundation, Mexico 4Department of Pulmonary and Critical Care Medicine, Médica Sur, Mexico 5National Institute of Respiratory Diseases (INER), Mexico 6Department of Pathology, National Institute of Respiratory Diseases (INER), Mexico 7Department of Radiology, National Institute of Respiratory Diseases (INER), Mexico 8National Autonomous University of Mexico, MexicoFulltext PDF
Objective(s): The aim of the present study was to assess the benefit of afatinib compared with gefitinib after chemotherapy progression in patients with advanced stage Epidermal Growth Factor Receptor (EGFR)-mutated lung adenocarcinoma. Methods: This was a retrospective single-center study that analyzed the disease-free survival of advanced stage EGFR-mutated lung adenocarcinoma that was treated with Tyrosine Kinase Inhibitors (TKIs) as a second or third-line treatment after chemotherapy. The study included patients with EGFR-mutated lung adenocarcinoma that was pathologically confirmed between 2011 and 2016 at the “Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío” (INER). The primary endpoint was progression-free survival after TKIs as a second or third-line treatment. Results: We included 61 patients, among whom 24 (39.3%) received afatinib and 37 (60.6%) received gefitinib. The median progression-free survival for patients treated with afatinib was 11 months, which was significantly longer compared with those treated with gefitinib (8 months). Conclusion: We found better progression-free survival in those treated with afatinib as a second or third-line treatment after chemotherapy compared with gefitinib, with similar results in response rate.
Epidermal growth factor receptor mutation; Non-small-cell lung cancer; Afatinib; Gefitinib; Progression-free survival; Lung adenocarcinoma; Chemotherapy; Tyrosine kinase inhibitor
Rodríguez-Cid JR, Arroyo-Hernandez M, Flores-Mariñelarena RR, Castro- Lopez CJ, Alatorre-Alexander JA, Martínez-Barrera L, et al. Second versus First-Generation Tyrosine Kinase Inhibitors in Lung Adenocarcinoma after Chemotherapy Progression. Clin Oncol. 2020; 5: 1746.